Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | NCF1 | P14598 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | TACR3 | P29371 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ACACA | Q13085 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11942312 | 0.90 | KDM4E (0.47) | KDM4ERENNCF1TP53MEN1 | |
| SCHEMBL8673292 | 0.83 | KDM4E (0.55) | KDM4EMEN1KMT2ALMNAHPGD | |
| SCHEMBL1228546 | 0.82 | REN (0.39) | KDM4ERENNCF1TP53KMT2A | |
| SCHEMBL1228082 | 0.81 | KDM4E (0.58) | KDM4ETP53TACR3MEN1KMT2A | |
| SCHEMBL4197109 | 0.81 | ALDH1A1 (0.45) | KDM4ENCF1MEN1KMT2ALMNA | |
| SCHEMBL8264291 | 0.81 | LTB4R (0.49) | KDM4ENCF1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL664247 | 0.81 | REN (0.42) | RENNCF1TP53TACR3MEN1 | |
| SCHEMBL661523 | 0.80 | KDM4E (0.41) | KDM4ERENNCF1TP53TACR3 | |
| SCHEMBL89580 | 0.78 | NCF1 (0.49) | NCF1LMNAHPGDSMN1; SMN2 | |
| SCHEMBL662410 | 0.77 | KDM4E (0.56) | KDM4ETP53MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190701-A1 | RENIN INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2467385-A1 | RENIN INHIBITORS | Merck Canada Inc. (CA) | 2012-06-27 | — | — | EP | disclosed |
| US-20120046293-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2012-02-23 | — | — | US | disclosed |
| US-8063105-B2 | Renin inhibitors | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| WO-2011020193-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2011-02-24 | — | — | WO | disclosed |
| US-20090281103-A1 | Renin Inhibitors | MERCK CANADA INC. (CA) | 2009-11-12 | — | — | US | disclosed |
| EP-1910272-A1 | RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007009250-A1 | RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046293-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | KDM4E 3884/4885REN 1/4885NCF1 3034/4885 |
| US-20120190701-A1 | RENIN INHIBITORS | REN, ACE, AGTR1 | KDM4E 3912/4885REN 1/4885NCF1 2805/4885 |
| US-20090281103-A1 | Renin Inhibitors | REN, ACE, AGT | KDM4E 3615/4885REN 1/4885NCF1 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.